CA3079523A1 - Glp-2 analogs and peptibodies for administration before, during or after surgery - Google Patents

Glp-2 analogs and peptibodies for administration before, during or after surgery Download PDF

Info

Publication number
CA3079523A1
CA3079523A1 CA3079523A CA3079523A CA3079523A1 CA 3079523 A1 CA3079523 A1 CA 3079523A1 CA 3079523 A CA3079523 A CA 3079523A CA 3079523 A CA3079523 A CA 3079523A CA 3079523 A1 CA3079523 A1 CA 3079523A1
Authority
CA
Canada
Prior art keywords
glp
patient
surgery
peptibody
bowel syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079523A
Other languages
English (en)
French (fr)
Inventor
Clark Pan
Angela Norton
Bettina Strack-Logue
Clement Olivier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire NPS Pharmaceuticals Inc filed Critical Shire NPS Pharmaceuticals Inc
Publication of CA3079523A1 publication Critical patent/CA3079523A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3079523A 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before, during or after surgery Pending CA3079523A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
PCT/US2018/059175 WO2019090209A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before during, or after surgery

Publications (1)

Publication Number Publication Date
CA3079523A1 true CA3079523A1 (en) 2019-05-09

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079523A Pending CA3079523A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before, during or after surgery

Country Status (14)

Country Link
US (1) US11660328B2 (https=)
EP (1) EP3706774A4 (https=)
JP (2) JP7296958B2 (https=)
KR (1) KR102825098B1 (https=)
CN (1) CN111629745A (https=)
AR (1) AR113835A1 (https=)
AU (1) AU2018360744A1 (https=)
BR (1) BR112020008936A2 (https=)
CA (1) CA3079523A1 (https=)
IL (1) IL274098B2 (https=)
MX (1) MX2020004620A (https=)
TW (1) TWI911137B (https=)
WO (1) WO2019090209A1 (https=)
ZA (1) ZA202002080B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003736A2 (pt) * 2017-08-22 2020-09-08 Shire-Nps Pharmaceuticals, Inc. polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809318B1 (en) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP2008247789A (ja) 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
JP6206972B2 (ja) 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
EP3082847A1 (en) * 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
RU2020118172A (ru) 2021-12-08
JP7296958B2 (ja) 2023-06-23
JP7752152B2 (ja) 2025-10-09
AU2018360744A1 (en) 2020-05-07
CN111629745A (zh) 2020-09-04
MX2020004620A (es) 2020-10-12
IL274098A (en) 2020-06-30
IL274098B1 (en) 2024-08-01
EP3706774A4 (en) 2021-09-08
EP3706774A1 (en) 2020-09-16
BR112020008936A2 (pt) 2020-10-20
AR113835A1 (es) 2020-06-17
ZA202002080B (en) 2025-11-26
US11660328B2 (en) 2023-05-30
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
IL274098B2 (en) 2024-12-01
KR20200085763A (ko) 2020-07-15
TW201922279A (zh) 2019-06-16
JP2023107883A (ja) 2023-08-03
US20210169986A1 (en) 2021-06-10
KR102825098B1 (ko) 2025-06-26
TWI911137B (zh) 2026-01-11

Similar Documents

Publication Publication Date Title
US11660328B2 (en) GLP-2 analogs and peptibodies for administration before, during or after surgery
KR102650991B1 (ko) 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
RU2606840C2 (ru) Композиция для лечения диабета, содержащая конъюгат инсулина длительного действия и конъюгат инсулинотропного пептида длительного действия
AU2014261111B2 (en) Therapeutic peptides
CN111108117B (zh) 胰高血糖素样肽1受体激动剂及其用途
AU2019218147B2 (en) FGF21 variant, fusion protein and application thereof
TW201410704A (zh) 長效胰島素及胰促泌素肽之液體製劑
CA2856967A1 (en) Therapeutic agents comprising insulin amino acid sequences
KR20110021758A (ko) 이형체-특이적 인슐린 유사체
TW202140065A (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
CN104144697A (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US20180280474A1 (en) Treatment of bile acid disorders
TW202136289A (zh) 新穎之胰島素類似物及其用途
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
CA3008392C (en) Ameliorating systemic sclerosis with death receptor agonists
WO2021263040A1 (en) Stable peptibody formulations
HK40008252A (en) A liquid formulation of long-acting insulin and insulinotropic peptide
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231026

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022